One of the end goals of any field aimed at human therapeutics is the eradication of disease. However, diseases such as HIV currently can't be cured, and treatments are aimed instead at ameliorating symptoms and stopping progression of the disease. With this in mind, I headed along to the Miltenyi commercial tutorial at Cyto '18, which was co-presented by
gave a talk on his work using closed-system sorting for stem cell-mediated HIV gene therapy, and gave the same talk at the Therapeutic Cell Sorting workshop.
Again, as in Christopher Groves talk, I saw a trend towards sterility becoming an issue as the applied therapeutic aspect of flow cytometry becomes more prominent.
Also outlined in his talk his was Stefan's own workflow targeting blood stem cells for gene therapy; allogenic transplantation from the patient, gene therapy based treatment on the transplant without expansion, and re-infusing the patient with their own modified cells. Interestingly, unlike CAR-T cell therapy, this process does not involve expansion of the population of target cells.
Stefan mentioned opportunities in the field; a figure of a potential 40 million patients whose lives could be improved by the use of gene therapy, the development of new tools, and the increasing number of clinical studies around this aspect (500+). He also discussed the challenges in the field - particularly the grade of consumables and reagents needed, and the need for labour to be done in a clean room.
Stefan's own background in flow cytometry is of note; he worked with Miltenyi on the evolution of the CliniMACS system to a portable version, and so has an in-depth understanding of the current capabilities and limitations of the field.
The talk was a refreshing look at the reality as well as the challenges of the human therapeutic applications of flow cytometry which were so talked about this year. I'll be watching this space to see when Stefan's work moves from a primate model into the clinic.
The work Stefan is doing is really pioneering the future of gene therapy, and was an encouraging look at the potentials of gene therapy to change people's lives for the better using this powerful technology.
Lina Chakrabarti, Christopher Groves and Michael Lee on the Challenges with Therapeutic Cell Sorting.
Read the complete available background
All Posts
Inish Cell Analyser
Cell Counting & Viability
Transfection Efficiencies
Microfluidic pumps
Microfluidic chips
Droplet Generation
Organ-on-Chip
Thrombosis
Platelet aggregation
Inish Solutions
Microfluidic Solutions
VenaFlux Solutions
COVID-19
Cell adhesion & migration
Inflammation
Label Free Analysis
Gene Transfection
#CellixTech
We are Cellix
Cellix Out and About
µTas
Cyto Conf 2018
Inish Cell Sorter
Cell Sorting
Stem cells
Search
Dr. Stefan Radtke: Innovative Flow Approaches Offer Hope to Patients.
Vivienne Williams
May 17, 2018
2 min read
Two weeks ago, the Cellix team travelled to Prague to participate in
Cyto 2018
, a conference discussing the cutting edge of flow cytometry research.
In the
third of a 4 part series
, we're looking at innovative applications for gene therapy.
One of the end goals of any field aimed at human therapeutics is the eradication of disease. However, diseases such as HIV currently can't be cured, and treatments are aimed instead at ameliorating symptoms and stopping progression of the disease. With this in mind, I headed along to the Miltenyi commercial tutorial at Cyto '18, which was co-presented by
Dr. Stefan Radtke
from the
Fred Hutchinson Cancer Research Centre
in Seattle.
Stefan
gave a talk on his work using closed-system sorting for stem cell-mediated HIV gene therapy, and gave the same talk at the Therapeutic Cell Sorting workshop.
Again, as in Christopher Groves talk, I saw a trend towards sterility becoming an issue as the applied therapeutic aspect of flow cytometry becomes more prominent.
Also outlined in his talk his was Stefan's own workflow targeting blood stem cells for gene therapy; allogenic transplantation from the patient, gene therapy based treatment on the transplant without expansion, and re-infusing the patient with their own modified cells. Interestingly, unlike CAR-T cell therapy, this process does not involve expansion of the population of target cells.
Stefan mentioned opportunities in the field; a figure of a potential 40 million patients whose lives could be improved by the use of gene therapy, the development of new tools, and the increasing number of clinical studies around this aspect (500+). He also discussed the challenges in the field - particularly the grade of consumables and reagents needed, and the need for labour to be done in a clean room.
Stefan's own background in flow cytometry is of note; he worked with Miltenyi on the evolution of the CliniMACS system to a portable version, and so has an in-depth understanding of the current capabilities and limitations of the field.
The talk was a refreshing look at the reality as well as the challenges of the human therapeutic applications of flow cytometry which were so talked about this year. I'll be watching this space to see when Stefan's work moves from a primate model into the clinic.
The work Stefan is doing is really pioneering the future of gene therapy, and was an encouraging look at the potentials of gene therapy to change people's lives for the better using this powerful technology.
For more info, read our other Cyto 2018 posts on:
Our 5 biggest takeaways from Cyto 2018
Lina Chakrabarti, Christopher Groves and Michael Lee on the Challenges with Therapeutic Cell Sorting.
Got a question for
Vivienne
about Cyto 2018? Get in touch via our
,
or email.
#DrStefanRadtke
#Fredhutchinson
#Cyto2018
#HIV
#FlowCytometry
#HumanTherapeutics
#CART
Gene Transfection
Cyto Conf 2018
Recent Posts
See All
Our annual Christmas Sale is back - Check it out before it’s over!
Inish Analyser Data Transfer Protocol
How to analyse data using the Inish Analyser?
For illustrations, downloads and the latest updates, visit the original published page.
View original Cellix reference